Supernus Pharmaceuticals | SUPN - Selling And Administration Expenses


Supernus Pharmaceuticals reported $133.64M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Abbott USD 3.6B 330M Jun/2026
ANI Pharmaceuticals USD 91.66M 18.01M Jun/2026
Aurora Cannabis CAD 41.4M 781K Mar/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Canopy Growth CAD 31.17M 2.27M Mar/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Corcept Therapeutics USD 156.9M 28.85M Jun/2026
Eisai JPY 114.83B 4.71B Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Pacira USD 91.81M 7.93M Jun/2026
Perrigo USD 3.28B 3.02B Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
United Therapeutics USD 206.7M 50.1M Jun/2026
Xeris Pharmaceuticals USD 53.14M 10.51M Mar/2026